甲状腺肿瘤患者外周血CD+4 CDHi25 CDLo127 调节性T细胞的检测及其临床意义

 目的　分析甲状腺肿瘤患者外周血CD+4 CDHi25 CDLo127 调节性T细胞（Treg）比例及其变化规律，初步探讨甲状腺肿瘤免疫抑制机制，以及分化型甲状腺癌和结节性甲状腺肿发病机制之间可能存在的相关性。方法　采用流式细胞技术联合标记CD4、CD25、CD127，检测43例初治分化型甲状腺癌患者（分化型甲状腺癌组）、132例初治结节性甲状腺肿患者（结节性甲状腺肿组）及153名健康者（健康对照组）的外周血T细胞各亚群和Treg 的比例。结果　分化型甲状腺癌组（6.48±1.49）%]及结节性甲状腺肿组（6.23±1.67）%]患者CD+4 CDHi25 CDLo127 Treg 比例均高于健康对照组（5.62±1.48）%]，差异有统计学意义（P＜0.05），而分化型甲状腺癌组及结节性甲状腺肿组之间，差异无统计学意义（P＞0.05）。结论　结节性甲状腺肿与分化型甲状腺癌患者外周血CD+4 CDHi25 CDLo127 Treg 比例较健康者均显著升高，提示CD+4 CDHi25 CDLo127 Treg 可能是甲状腺肿瘤患者免疫抑制的重要原因之一。

Detection and its clinical significance of CD+4 CDHi25 CDLo127 regulatory T cells in peripheral blood of patients with thyroid neoplasm

Objective To analyze CD+4 CDHi25 CDLo127 regulatory T cells (Treg) in peripheral blood of patients with thyroid nodules and differentiated thyroid cancer and their change regularity, and to investigate the immunosuppression mechanism. Methods The peripheral blood was collected from 175 patients with thyroid nodules, including 43 patients with differentiated thyroid cancer and 132 patients with nodular goiter.By using monoclonal antibodies, the blood samples were evaluated with the flow cytomertry for lymphocyte subsets and Treg cells. Results The results showed the prevalence of the CD+4 CDHi25 CDLo127 Treg in differentiated thyroid cancer group (6.48±1.49) %] and nodular goiter group (6.23+1.67) %] was higher than those in the healthy group (5.62±1.48) %], and the difference was significant(P < 0.005), but there was no significant difference between the nodular goiter group and differentiated thyroid cancer group (P >0.005).Conclusion It is concluded that the relative increase of CD+4 CDHi25 CDLo127 Treg in peripheral blood of patients with nodular goiter and differentiated thyroid cancer may be related to immunosuppression and tumor progression.